Adeno-associated virus (AAV) gene therapy administered via bilateral

Class

Adeno-associated virus (AAV) gene therapy administered via bilateral stereotactic injection into the substantia nigra (specific transgene not disclosed in available records)

Notes

original target text: Adeno-associated virus (AAV) gene therapy administered via bilateral stereotactic injection into the substantia nigra (specific transgene not disclosed in available records)

This entry describes a gene therapy administered through direct neurosurgical delivery rather than by injection into the bloodstream. The vector is an adeno-associated virus (AAV), a small, non-replicating virus commonly re-engineered as a shuttle for genetic material because it infects cells efficiently but does not cause disease and, in most formulations, does not insert its cargo into the host genome. Here the vector is injected stereotactically—using imaging-guided coordinates for precise placement—into the substantia nigra on both sides of the brain. The substantia nigra is the region containing dopamine-producing neurons whose progressive loss underlies Parkinson's disease, making it the anatomical rationale for this delivery approach even though the specific genetic payload (transgene) is not disclosed in the available records. Direct injection into this structure allows the therapy to reach the relevant neurons at high concentration while limiting exposure of the rest of the brain and body, which can reduce systemic immune reactions and off-target effects compared with intravenous administration. Across this class of therapies, transgenes have variously aimed to restore enzymes needed for dopamine synthesis, supply neurotrophic (nerve-supporting) factors, or correct or suppress disease-causing genes. Without knowing which strategy this program uses, only the delivery platform and its general disease rationale can be described with confidence.